Potential of immunosuppressive agents in cerebral ischaemia.

Simple item page
dc.contributor.authorGupta, Yogendra Kumar
dc.contributor.authorChauhan, Anjali
dc.date.accessioned2011-11-18T04:59:55Z
dc.date.available2011-11-18T04:59:55Z
dc.date.issued2011-01
dc.description.abstractIschaemic stroke is a disorder involving multiple mechanisms of injury progression including activation of glutamate receptors, release of proinflammatory cytokines, nitric oxide (NO), free oxygen radicals and proteases. Presently, recombinant tissue plasminogen activator (rtPA) is the only drug approved for the management of acute ischaemic stroke. This drug, however, is associated with limitations like narrow therapeutic window and increased risk of intracranial haemorrhage. A large number of therapeutic agents have been tested including N-methly-D-aspartate (NMDA) receptor antagonist, calcium channel blockers and antioxidants for management of stroke, but none has provided significant neuroprotection in clinical trials. Therefore, searching for other potentially effective drugs for ischaemic stroke management becomes important. Immunosuppressive agents with their wide array of mechanisms have potential as neuroprotectants. Corticosteroids, immunophilin ligands, mycophenolate mofetil and minocycline have shown protective effect on neurons by their direct actions or attenuating toxic effects of mediators of inflammation. This review focuses on the current status of corticosteroids, cyclosporine A, FK506, rapamycin, mycophenolate mofetil and minocycline in the experimental models of cerebral ischaemia.en_US
dc.identifier.citationGupta Yogendra Kumar, Chauhan Anjali. Potential of immunosuppressive agents in cerebral ischaemia. Indian Journal of Medical Research. 2011 Jan; 133(1): 15-26.en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/135346
dc.language.isoenen_US
dc.source.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3100142/en_US
dc.subjectCerebral ischaemiaen_US
dc.subjectimmunosuppressantsen_US
dc.subjectin vitro and in vivo modelsen_US
dc.subjectneuroprotectionen_US
dc.subject.meshBrain Ischemia --drug therapy
dc.subject.meshBrain Ischemia --pathology
dc.subject.meshCell Death --physiology
dc.subject.meshFibrinolytic Agents --therapeutic use
dc.subject.meshHumans
dc.subject.meshImmunosuppressive Agents --therapeutic use
dc.subject.meshNerve Degeneration --pathology
dc.subject.meshNerve Degeneration --physiopathology
dc.subject.meshNeuroprotective Agents --therapeutic use
dc.subject.meshSteroids --therapeutic use
dc.subject.meshStroke --drug therapy
dc.subject.meshStroke --pathology
dc.subject.meshTissue Plasminogen Activator --therapeutic use
dc.titlePotential of immunosuppressive agents in cerebral ischaemia.en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijmr2011v133n1p15.pdf
Size:
408 KB
Format:
Adobe Portable Document Format
Description:
Journal article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Indian Journal of Medical Research